SEARCH:   Advanced

Blood, 12 February 2009, Vol. 113, No. 7, pp. 1412-1421. Prepublished online as a Blood First Edition Paper on December 12, 2008; DOI 10.1182/blood-2008-08-175653. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-08-175653v1 113/7/1412    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Illidge, T. M. Articles by Johnson, P. W. M. Search for Related Content PubMed PubMed Citation Articles by Illidge, T. M. Articles by Johnson, P. W. M. Related Collections Free Research Articles Lymphoid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy Tim M. Illidge1, Mike Bayne2,3, Nicholas S. Brown1, Samantha Chilton3, Mark S. Cragg3, Martin J. Glennie3, Yong Du4, Valerie Lewington5,6, James Smart3, James Thom6, Maureen Zivanovic7, and Peter W. M. Johnson3 1 School of Cancer and Imaging Sciences, University of Manchester, Manchester; 2 Department of Clinical Oncology, Poole Hospital National Health Service (NHS) Foundation Trust, Poole; 3 Cancer Sciences Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton; 4 Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London; 5 Department of Nuclear Medicine, Royal Marsden NHS Foundation Trust, Sutton; 6 Department of Nuclear Medicine, Southampton University Hospitals NHS Trust, Southampton; and 7 Department of Nuclear Medicine, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom The effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m2 rituximab followed by 2 fractions of 131I-rituximab, preceded by a 100-mg/m2 predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of 131I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of 131I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent 131I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of 131I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF] T. Illidge and Y. Du When is a predose a dose too much? Blood, June 4, 2009; 113(23): 6034 - 6035. [Full Text] [PDF] R. M. Sharkey, O. W. Press, and D. M. Goldenberg A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy Blood, April 23, 2009; 113(17): 3891 - 3895. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020